Page last updated: 2024-09-05

tolvaptan and Polyuria

tolvaptan has been researched along with Polyuria in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Ding, L; Gong, L; Jiang, W; Lu, J; Qian, X; Tang, W; Xie, F; Xu, M; Xu, W1
Hirose, T; Ito, S; Kinugasa, S; Mori, T; Muroya, Y; Oba-Yabana, I; Ohsaki, Y; Sato, E; Takahashi, C; Wang, A1
Boertien, WE; Gansevoort, RT; Kramers, BJ; Meijer, E; van Gastel, MDA1
Emoto, M; Fujimoto, K; Inaba, M; Ishimura, E; Machiba, Y; Mori, K; Nakatani, A; Nakatani, S; Okute, Y; Tsuda, A; Uedono, H1
Bae, KT; Casteleijn, NF; Higashihara, E; Kappert, P; Leliveld, AM; Meijer, E; Messchendorp, AL; Torres, V1
Cho, C; Lien, YH; Logan, JL1

Reviews

1 review(s) available for tolvaptan and Polyuria

ArticleYear
Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis.
    International urology and nephrology, 2023, Volume: 55, Issue:3

    Topics: Abdominal Pain; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Hematuria; Humans; Hypertension; Polycystic Kidney, Autosomal Dominant; Polyuria; Tolvaptan

2023

Trials

2 trial(s) available for tolvaptan and Polyuria

ArticleYear
Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019, Volume: 73, Issue:3

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Polyuria; Prospective Studies; Tolvaptan

2019
Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients.
    Clinical and experimental nephrology, 2017, Volume: 21, Issue:3

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Netherlands; Polycystic Kidney, Autosomal Dominant; Polyuria; Receptors, Vasopressin; Risk Factors; Time Factors; Tolvaptan; Treatment Outcome; Ureter; Urodynamics

2017

Other Studies

3 other study(ies) available for tolvaptan and Polyuria

ArticleYear
Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats.
    Clinical and experimental nephrology, 2019, Volume: 23, Issue:4

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Blood Pressure; Diuretics; Drug Therapy, Combination; Gene Expression; Glomerular Filtration Rate; Hydrochlorothiazide; Male; Nitric Oxide Synthase Type I; Polycystic Kidney Diseases; Polyuria; Prostaglandin-E Synthases; Rats; Renin; RNA, Messenger; Tolvaptan; Urine

2019
Novel increasing dose regimen of tolvaptan for autosomal dominant polycystic kidney disease in patient with low tolerability.
    Nephrology (Carlton, Vic.), 2018, Volume: 23, Issue:8

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Polycystic Kidney, Autosomal Dominant; Polyuria; Tolvaptan; Treatment Outcome

2018
Massive aquaresis after tolvaptan administration and albumin infusion in a patient with alcoholic cirrhosis.
    The American journal of medicine, 2012, Volume: 125, Issue:1

    Topics: Adult; Albumins; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Hyponatremia; Infusions, Intravenous; Liver Cirrhosis, Alcoholic; Male; Polyuria; Tolvaptan

2012